VistaGen Therapeutics, Inc.
NASDAQ:VTGN
3.12 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.064 | -0.227 | 1.109 | 1.09 | 0 | 0 | 0 | 1.25 | 0 | 0 | 0 | 0.2 | 1.342 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.568 | 0.51 | 0.815 | 0 | 0.103 | 0.091 | 0.081 | 0 | 0.054 | 0 | 0 | 3.431 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.496 | -0.737 | 0.294 | 1.09 | -0.103 | -0.091 | -0.081 | 1.25 | -0.054 | 0 | 0 | -3.23 | 1.342 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.466 | 3.243 | 0.265 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | -16.12 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 20.022 | 44.275 | 35.408 | 12.476 | 13.374 | 17.099 | 7.763 | 5.204 | 3.932 | 2.433 | 2.481 | 3.431 | 5.389 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 14.063 | 12.76 | 10.452 | 6.547 | 6.6 | 7.432 | 6.437 | 5.868 | 13.919 | 4.246 | 2.548 | 3.055 | 4,997,000 | 0.008 | 0.022 | 0.016 | 0.005 |
| Selling & Marketing Expenses
| 0 | 1.904 | 2.796 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4,996,995.003 | 0 | 0 | 0 | 0 |
| SG&A
| 14.063 | 14.178 | 13.248 | 6.547 | 6.6 | 7.432 | 6.437 | 5.868 | 13.919 | 4.246 | 2.548 | 3.055 | 4.997 | 0.009 | 0.022 | 0.016 | 0.005 |
| Other Expenses
| 0.312 | 0 | 0 | 0.001 | -0.827 | -0.049 | -0.428 | -0.427 | -0.002 | -0.233 | 0 | -0.473 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 34.085 | 58.454 | 48.656 | 19.023 | 19.974 | 24.531 | 14.2 | 11.072 | 17.85 | 6.679 | 5.029 | 6.486 | 10.386 | 0.009 | 0.022 | 0.016 | 0.005 |
| Operating Income
| -33.021 | -59.191 | -47.779 | -17.934 | -20.802 | -24.556 | -14.2 | -10.249 | -17.85 | -6.777 | -5.029 | -6.793 | -9.043 | -0.009 | -0.022 | -0.016 | -0.005 |
| Operating Income Ratio
| -31.035 | 260.407 | -43.087 | -16.461 | 0 | 0 | 0 | -8.199 | 0 | 0 | 0 | -33.898 | -6.738 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.663 | -0.051 | 0.02 | 0.002 | 0.03 | -0.049 | -0.135 | -0.427 | -28.591 | -2.593 | 3.616 | -5.623 | -1.271 | -0.009 | -0.022 | 0 | 0 |
| Income Before Tax
| -29.358 | -59.242 | -47.759 | -17.932 | -20.771 | -24.587 | -14.344 | -10.253 | -47.218 | -13.883 | -2.965 | -12.883 | -12.208 | -0.009 | -0.022 | -0.016 | -0.005 |
| Income Before Tax Ratio
| -27.592 | 260.633 | -43.069 | -16.459 | 0 | 0 | 0 | -8.202 | 0 | 0 | 0 | -64.286 | -9.095 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.004 | 0.006 | 0.003 | 0.003 | 0.003 | 0.003 | 0.002 | 0.002 | 0.002 | 0.002 | 0.003 | 0.004 | 0.002 | 0 | 0 | 0 | -0 |
| Net Income
| -29.358 | -59.248 | -47.762 | -17.934 | -20.774 | -24.59 | -14.346 | -10.256 | -47.221 | -13.886 | -2.968 | -12.887 | -12.21 | -0.009 | -0.022 | -0.016 | -0.005 |
| Net Income Ratio
| -27.592 | 260.659 | -43.072 | -16.461 | 0 | 0 | 0 | -8.204 | 0 | 0 | 0 | -64.305 | -9.097 | 0 | 0 | 0 | 0 |
| EPS
| -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.28 | -318.27 | -114.28 | -426.99 | -497.11 | -0.46 | -1.13 | -0.95 | 0 |
| EPS Diluted
| -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.27 | -315.87 | -81 | -426.98 | -497.11 | -0.46 | -1.13 | -0.95 | 0 |
| EBITDA
| -33.021 | -58.681 | -46.816 | -17.801 | -20.653 | -24.439 | -14.2 | -10.193 | -17.799 | -6.848 | -4.964 | -6.695 | -8.998 | -0.009 | -0.022 | -0.016 | -0.005 |
| EBITDA Ratio
| -31.035 | 258.165 | -42.218 | -16.339 | 0 | 0 | 0 | -8.155 | 0 | 0 | 0 | -33.406 | -6.704 | 0 | 0 | 0 | 0 |